Skip to main content

Table 3 Univariate and multivariate analysis using Cox regression hazards model

From: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death

Univariate analysis Multivariate analysis
  HR (95% CI) p-value Model HR (95% CI) p-value
Age 0.996 (0.970–1.023) 0.783 Base model
Male 0.638 (0.281–1.446) 0.282  LGE% 1.081 (1.044–1.120) <  0.001
Known AF 3.299 (1.425–7.637) 0.005  Known AF 2.421 (0.903–6.490) 0.079
Unexplained syncope 0.926 (0.274–3.131) 0.901  LVEF 1.006 (0.951–1.064) 0.844
Family history of SCD 0.711 (0.236–2.682) 0.711  Left atrial size 1.036 (0.974–1.102) 0.259
NSVT 2.134 (0.903–5.042) 0.084  NSVT 1.121 (0.441–2.848) 0.810
Left atrial size 1.060 (1.016–1.105) 0.007 With HCM Risk-SCD
LVOTO 1.004 (0.992–1.015) 0.516  HCM Risk-SCD 0.970 (0.866–1.086) 0.596
LVM > 30 mm 1.194 (0.516–2.763) 0.679  LGE% 1.087 (1.053–1.123) < 0.001
LVMi 1.003 (0.995–1.011) 0.478 With ACCF/AHA
LVEF 0.951 (0.903–1.002) 0.057   ‘ICD not recommended’ reference
LGE% 1.083 (1.052–1.116) < 0.001   ‘ICD can be useful’ 1.971 (0.664–5.847) 0.221
HCM Risk-SCD 1.034 (0.944–1.132) 0.476   ‘ICD reasonable’ 0.966 (0.354–2.636) 0.946
ACCF/AHA  LGE% 1.082 (1.049–1.117) < 0.001
  ‘ICD not recommended’ reference    
  ‘ICD can be useful’ 3.053 (1.058–8.809) 0.039    
  ‘ICD reasonable’ 1.698 (0.652–4.422) 0.278    
  1. ACCF/AHA American College of Cardiology Foundation / American Heart Association, AF atrial fibrillation, HCM Risk-SCD hypertrophic cardiomyopathy sudden cardiac death risk tool, ICD implantable cardiac defibrillator, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction, LVMi left ventricular mass, indexed to body surface area, LVOTO left ventricular outflow tract obstruction, NSVT non-sustained ventricular tachycardia at Holter monitoring, SCD sudden cardiac death